Paul R. Kirchgraber - 19 May 2023 Form 4 Insider Report for LABORATORY CORP OF AMERICA HOLDINGS (LH)

Role: CEO, Covance Drug Development
Signature: /s/ Sandra van der Vaart, Attorney-in-Fact for Paul R. Kirchgraber
Issuer symbol: LH
Transactions as of: 19 May 2023
Net transactions value: -$147,914
Form type: 4
Filing time: 23 May 2023, 08:06:26 UTC
Previous filing: 03 Apr 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	LH	Common Stock	Options Exercise	$784,793	+4,300	+33%	$182.51	17,246	19 May 2023	Direct
transaction	LH	Common Stock	Sale	$932,707	-4,300	-25%	$216.91	12,946	19 May 2023	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LH	Non-qualified Stock Options	Options Exercise	$0	-4,300	-100%	$0.000000^*	0	19 May 2023	Common Stock	4,300	$182.51	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan.
F2	The option vested in three equal annual installments beginning on the date reflected in this column.